http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
전신성 홍반성 낭창 환자에서 항 cardiolipin항체와 루프스 항응고인자의 출현 빈도와 임상적 의의
강문수,윤종수,강천일,서영익,황윤근,이종명,김능수 慶北大學校 醫科大學 1994 慶北醫大誌 Vol.35 No.3
목적 : 전신성홍반성낭창으로 확진된 환자들을 대상으로 항 cardiolipin,항체와 루프스 항응고인자의 출현 빈도와 임상 증상, 검사 소견 및 치료약제와의 관계를 분석하고 임상적 의의를 조사하였다. 대상 및 방법 : 전신성홍반성낭창으로 확진된 21예를 대상으로 하였으며 임상 및 검사소견을 분석하였고 항 cardiolipin항체는 ELISA법으로 측정하였고 루프스 항응고인자는 Kaolin clotting time 및 Platelet neutralization procedure를 함께 시행하여 측정하였다. 결과 : 전신성홍반성낭창 21예에서 항 cardiolipn항체는 6예(28.5%)에서 양성이었으며, 루프스 항응고인자는 단 1예(4.7%)에서 양성이었다. 항 cardiolipin항체 양성군과 음성군 사이에 연령, 성별 및 질병기간은 차이가 없었으며 광 과민성, 레이노 현상, 혈관염, 근관절증상, 심폐계증상, 신장병변 등의 임상소견도 차이가 없었다. 자연유산의 경험은 양성군에서 2예(40%), 음성군에서 1예(12.5%)에서 있었으며, 혈전증은 양성군 1예에서만 발생하였다. 양성군과 음성군사이에 빈혈, 백혈구감소증, 혈소판감소증, prothrombin time의 연장, 항핵 항체, 항 dsDNA항체, 혈청 보체감소 등의 검사 소견은 통계학적으로 차이가 없었다. 항 cardiolipin항체 양성군과 음성군사이에 IgG와 IgA치는 차이가 없었으나 IgM과 IgE치는 양성군에서 음성군보다 통계학적으로 유의하게 높았다. (P<0.05) 결론 : 항 cardiolipin항체와 혈전중, 자연유산, 혈소판감소증 및 혈관염 사이에는 별다른 상관관계를 발견할 수 없었으며 항 cardiolipin항체 양성군의 IgM및 IgE치의 증가가 질병의 활성도에 따른 변화 때문으로 생각되나 항 cardiolipin항체와의 직접적인 상관관계가 있을 가능성도 배제할 수 없을 것으로 생각된다. 전신성홍반성낭창환자에서 항 cardiolipin항체 양성군의 임상적 의의에 대해서 논란의 여지가 있으나 앞으로 더 많은 환자를 대상으로 이들의 임상적 의미에 대한 연구가 필요할 것으로 생각되며 또한 cardiolipin 이외의 각종 인지질에 대한 연구가 요구된다고 사료된다. We evaluated the prevalence of anti-cardiolipin antibodies and lupus anticoagulant in 21 patients with systemic lupus erythematosus(SLE) and investigated whether the presence of anti-cardiolipin antibodies was associated with paticular clinical or laboratory features. The prevalence of anti-cardiolipin antibodies was 28.5% and that of lupus anticoagulant was 4.7% in patients with SLE. No statistically significant association could be found between anti-cardiolipin antibodies and recurrent abortion, thrombosis, thrombocytopenia, and false positive VDRL. But there were significant association between anti-cardiolipin antibodies and serum immunoglobulin M, immunoglobulin E levels. Also, Various therapeutic regimens, including corticosteroids or antimalarial agents had no effect on the presence of anti-cardiolipin antibodies. Further studies are needed to clarify the pathogenetic role and clinical significance of anticardiolipin antibody, lupus anticoagulant.
이양원 ( Yang Won Lee ),김지민 ( Ji Min Kim ),김윤경 ( Yun Kyeong Kim ),문수진 ( Su Jin Moon ),윤호성 ( Ho Sung Yoon ),김호연 ( Ho Youn Kim ),박성환 ( Sung Hwan Park ) 대한내과학회 2011 대한내과학회지 Vol.80 No.3
Patients with systemic lupus erythematosus (SLE) have a 25% to 50% incidence of abnormal findings on liver function tests. The main causes of abnormal liver function in patients with SLE are viral hepatitis, drug-induced toxic hepatitis, and fatty liver. However, hepatic involvement due to the pathogenic process of SLE is rare. In such conditions, lupus-related hepatitis must be distinguished from autoimmune hepatitis, which is a type of primary liver disease characterized by similar clinical manifestations and autoimmune profiles. Relationships between hepatic involvement of SLE and autoimmune hepatitis remain to be elucidated. We report a case of lupus-related hepatitis mimicking autoimmune hepatitis. (Korean J Med 2011;80:360-364)
윤장욱,박상훈,김은정,홍지현,이형석,오길찬,박철희,한태호,이동근,김종혁,박혜림,박충기 대한간학회 2003 Clinical and Molecular Hepatology(대한간학회지) Vol.9 No.3
Autoimmune hepatitis (AIH) is a chronic necroinflammatory liver disease of unknown cause associated with circulating autoantibodies and high serum globulin level. Systemic lupus erythematosus (SLE) is a disease of unknown etiology in which tissues and cells are damaged by pathogenic autoantibodies and immune complex, affecting multiple organs including the liver, kidney, and CNS. The difference between the hepatic involvement of SLE and autoimmune hepatitis has not been clearly defined in the past due to similarities in clinical and biochemical features. A scoring system for the diagnosis of AIH has been established, and AIH and SLE associated hepatitis have been defined as two different entities, although both have the same autoimmune features such as polyarthralgia, hypergammaglobulinemia and circulating autoantibodies. AIH has been considered to occur infrequently in SLE. We report two cases of AIH which simultaneously satisfied the criteria of SLE.(Korean J Hepatol 2003;9:231-235)
전신성 홍반성 루푸스를 동반한 임산부 94예의 임신 경과 및 산과적 고찰
안현영 ( Hyun Young Ahn ),김연희 ( Yeon Hee Kim ),길기철 ( Ki Chul Kil ),박인양 ( In Yang Park ),이귀세라 ( Guisera Lee ),김사진 ( Sa Jin Kim ),박성환 ( Sung Hwan Park ),신종철 ( Jong Chul Shin ) 대한산부인과학회 2008 Obstetrics & Gynecology Science Vol.51 No.2
Objective: The purpose of this study was to assess the maternal and fetal outcomes in pregnant women with systemic lupus erythematosus (SLE) and to evaluate clinical and laboratory markers for preterm birth and lupus flares. Methods: 94 pregnancies of 60 patients were retrospectively evaluated from Jan 1997 to Sep 2004. We used clinical and laboratory data from the medical records and statistics analysis by Chi-square test, using SPSS 15.0 V. Results: Pregnancy resulted in 74 (78.7%) live births, 11 (11.7%) spontaneous abortions, 2 (2.1%) therapeutic abortion, and 4 (4.2%) stillbirths. Thirty-seven cases (47.4%) were delivered by cesarean section. Obstetric complications included 17.9% of preterm births, 26.9% of preeclampsia, and 20.5% of IUGR. There were 31 (39.7%) uncomplicated cases among the pregnancies over 20 gestational weeks. There were 12 of transient neonatal lupus, 2 of neonatal death due to prematurity, and 51 of normal births. Low C4, myocarditis, pleural effusion prior to pregnancy, activity at conception, antiphospholipid antibody syndrome were significantly associated with preterm birth. The maternal long-term effect of pregnancy was poor, because 44.7% were in deterioration of cardiovascular, hematologic or renal function after delivery. Lupus nephritis, proteinuria, hematuria, and activity at conception were significantly associated with lupus flare during pregnancy. Conclusion: Pregnant women with active SLE at conception should be intensively monitored with maternal and fetal surveillance. It is essential to control disease activity during pregnancy. However, adequate pregnancy follow-up and delivery care by multidisciplinary effort with experience in management of patients with SLE resulted in a better outcome of lupus pregnancy.
A Case of Intracranial Tuberculoma in a Patient with Systemic Lupus Erythematosus
Ahn, Hong Joon,Han, Sung Hoon,Kim, Dong Wook,Lee, Yun Woo 인제대학교 2000 仁濟醫學 Vol.21 No.2
전신성 홍반성 루푸스 환자는 면역력이 저하되어 감염의 위험이 증가된다. 또한 치료를 위하여 장기간 당질스테로이드를 복용하므로 감염의 위험이 더 증가한다. 그러나 국내에서는 루푸스 환자에 병발한 두개내 결핵종 1예를 경험하였기에 문헌고찰과 함께 보고한다. 환자는 34세 여자로서 4년 반 전부터 전신성 홍반성 루푸스로 치료 받아 왔으며 5개월 전부터 중추신경계 루프스 치료를 위해 스테로이드와 cyclophosphamide 충격요법을 실시하였다. 두통이 심하여 실시한 뇌의 자기공명영상에 여러개의 결절이 관찰되었고 조직 검사에 건락괴사를 동반하는 만성 육아종성 염증이 관찰되었다. 조직의 Ziehl-Neelsen 염색에 항산성 간균이 관찰되었고 결핵균 PCR 검사가 양성이었으나 결핵균 배양은 되지 않았다.
이신석 ( Shin Seok Lee ) 대한내과학회 2007 대한내과학회지 Vol.73 No.6
The survival of patients with systemic lupus erythematosus (SLE) has improved dramatically over the last few decades. However, the mortality rates of SLE patients remain three times that of an age- and gender-matched population. As the lifespan of SLE patients continues to increase, death due to cardiovascular disease (CVD) has attained increasing importance. In several SLE cohorts, the prevalence of clinical coronary artery disease (CAD) has been shown to range from 6% to 10%. Compared with women in the general population, women with SLE are estimated to be 5-8-times more likely to develop CAD, with this risk being particularly marked in women younger than 55 years of age. These increased risks of CVD for SLE patients cannot be fully explained by traditional cardiovascular risk factors alone and other factors, such as inflammatory factors, are presumed to contribute to these risks. Among the inflammatory factors, high-sensitivity C-reactive protein (hsCRP) has proven to be the most powerful marker for future cardiovascular events in patients with SLE. It is suggested that the addition of hsCRP to standard cardiovascular risk factors will facilitate the identification of lupus patients at risk for future cardiovascular events. (Korean J Med 73:556-564, 2007)